Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.60 |
| ▸ | IL2 | P60568 | 7/20 | 0.60 |
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593048 | 0.89 | MAP4K1 (0.57) | MAP4K1IL2 | |
| SCHEMBL21593019 | 0.88 | MAP4K1 (0.49) | MAP4K1IL2DYRK1A | |
| SCHEMBL21593018 | 0.87 | TNIK (0.48) | MAP4K1IL2DYRK1A | |
| SCHEMBL21592801 | 0.85 | MAP4K1 (0.61) | MAP4K1IL2KITDYRK1AAAK1 | |
| SCHEMBL21592993 | 0.83 | MAP4K1 (0.51) | MAP4K1IL2 | |
| SCHEMBL28597640 | 0.82 | PAK1 (0.56) | MAP4K1IL2 | |
| SCHEMBL21593051 | 0.80 | MAP4K1 (0.52) | MAP4K1 | |
| SCHEMBL28513753 | 0.80 | MAP4K1 (0.62) | MAP4K1IL2KITDYRK1AAAK1 | |
| SCHEMBL21592786 | 0.80 | MAP4K1 (0.62) | MAP4K1IL2 | |
| SCHEMBL21592637 | 0.79 | MAP4K1 (0.59) | MAP4K1IL2KITDYRK1AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |